Boston Scientific Corporation $BSX Shares Newly Bought by First Nebraska Trust Co

First Nebraska Trust Co acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 111,039 shares of the medical equipment provider’s stock, valued at approximately $4,847,000.

Other hedge funds have also added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of Boston Scientific during the first quarter worth approximately $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at approximately $32,000. Measured Wealth Private Client Group LLC boosted its holdings in shares of Boston Scientific by 244.9% in the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares during the period. Kelleher Financial Advisors bought a new position in Boston Scientific in the second quarter worth approximately $25,000. Finally, Nvwm LLC grew its stake in Boston Scientific by 526.2% in the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 542 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Shares of BSX opened at $43.58 on Wednesday. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $105.65. The company has a 50 day moving average of $44.55 and a two-hundred day moving average of $56.38. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $63.15 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 1.29 and a beta of 0.60.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period last year, the business posted $0.75 earnings per share. The firm’s revenue was up 1.4% compared to the same quarter last year. As a group, analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on BSX shares. UBS Group reduced their price objective on Boston Scientific from $67.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, October 29th. BTIG Research lowered their target price on Boston Scientific from $56.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, October 29th. Stifel Nicolaus dropped their price target on Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Oppenheimer lowered Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 29th. Finally, Deutsche Bank Aktiengesellschaft set a $48.00 price target on Boston Scientific and gave the company a “buy” rating in a research note on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $61.43.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported that the SIMPLAAFY trial of its WATCHMAN FLX Pro heart device met its six-month primary endpoints. The results found two post-implant drug regimens non-inferior to dual-antiplatelet therapy, potentially supporting simpler treatment after the procedure. Article: SIMPLAAFY study results
• Neutral Sentiment: Boston Scientific and Blackstone Life Sciences announced a $455 million collaboration to co-develop the VITALYST heart-pump technology. The arrangement may ease near-term development costs, but an analyst noted it could defer growth and leave longer-term uncertainty. Article: VITALYST collaboration Article: Analyst assessment of VITALYST deal
• Negative Sentiment: A Zacks analysis flagged weakening earnings estimates, softer momentum in core businesses and major growth catalysts that may not arrive until 2028. Those concerns could overshadow the company’s valuation discount. Article: Valuation and earnings-growth analysis
• Negative Sentiment: J.P. Morgan maintained a Hold rating, while TD Cowen also cut its rating to Hold; Barclays lowered its price target. The cautious analyst stance adds to concerns about near-term growth. Article: J.P. Morgan rating Article: TD Cowen rating Article: Barclays price-target change

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.